ZM reports Q1 fiscal 2027 results after the close on May 21 — and the setup heading in is notably less comfortable than a month ago. The stock has given back 5.4% this week to $97.39, reversing part of its 10.6% April gain, while short sellers have been quietly adding exposure and a pair of analysts lifted targets just days before the print.
Short interest has climbed steadily all month. It rose 11% over the past week and is now up more than 15% from a month ago, reaching 2.7% of the free float. That absolute level remains low by any historical standard, and borrowing the stock is essentially free — cost to borrow is 0.48%, up about 15% on the week but still well within the range of the past 30 days. The borrow market itself is extremely loose: availability is at 4,509% of short interest, meaning shares to borrow vastly outnumber those already lent out. Shorts face no supply constraints here. The picture is one of a steady, unhurried build — not a crowded or aggressive short attack.
Options positioning has edged slightly more defensive without flashing an alarm. The put/call ratio is 0.56, running a little above its 20-day average of 0.53 — about 1.2 standard deviations above the mean. That's a mild lean toward downside protection, not a panicked hedge. The 52-week range on the PCR runs from 0.44 to 0.89, so current positioning is nowhere near the fearful end of the dial. The overall read from the lending and options markets: cautious, not scared.
The Street has been actively revising ahead of the report. Citigroup lifted its target to $122 last Thursday, maintaining its Buy rating — the more bullish end of the analyst spectrum. Baird followed on Tuesday, raising its target to $105 while keeping Outperform. Both moves came pre-earnings and reflect confidence in the platform's direction. Not everyone is aligned: Citizens reiterated Market Perform on Wednesday with no target, and Keybanc sits at Underweight with a $74 target — well below the current price. The 13 buy ratings dominate the consensus, but the range of conviction is wide. Bulls point to Zoom's progress toward 30% GAAP operating margins, its AI product expansion, and a balance sheet that needs no external capital. Bears flag churn risk from hyperscaler rivals and softening forward EPS momentum — the 12-month forward EPS growth factor ranks in just the 6th percentile. Valuation is not stretched on most metrics: the P/E is around 16x, EV/EBITDA near 9.5x, and that ratio has compressed slightly over the past month.
The earnings history provides the starkest data point of the week. The February 2026 print delivered a one-day drop of nearly 14%, extending to a five-day loss of roughly 11%. The prior quarter's results also generated a five-day loss exceeding 14%. Two consecutive sharp post-earnings declines set a clear pattern of sell-the-news behaviour regardless of the headline numbers. The current week's 5% pullback may partly reflect that muscle memory among holders.
Insider activity has been net selling. Founder and CEO Eric Yuan offloaded shares across multiple tranches on May 4–5, collecting just over $1.1m in total proceeds around the $107 level — a price now above where the stock closed Tuesday. Director Santiago Subotovsky also sold approximately $562,000 worth of stock on May 4. The 90-day net for insiders is positive in share count, but that reflects option-related mechanics rather than open-market conviction buying. JP Morgan Asset Management added a notable 3.5 million shares in the most recent quarter, and Alyeska Investment Group added nearly 2.8 million — two of the largest institutional moves visible in the holder data.
The result tomorrow evening is therefore the next decisive input: whether the EPS surprise track record (which ranks in the 83rd percentile) can offset a market that has twice punished the stock in the days following a print.
See the live data behind this article on ORTEX.
Open ZM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
